IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Zacks News
The Zacks Analyst Blog Highlights: Moderna, Lonza Group, BMW, NXP Semiconductors and IDEXX Laboratories
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Lonza Group, BMW, NXP Semiconductors and IDEXX Laboratories
Vaccine Data Propels Stocks: Global Week Ahead
by John Blank
Moderna said in a Phase 3 trial, which enrolled 30K patients, its vaccine demonstrated 94.5% efficacy. The trial included "many high-risk or elderly" people. Furthermore, their vaccine can be stored a temperatures a commercial freezer can likely supply, easing distribution concerns.
Medtronic (MDT) Integrates InPen With Guardian Connect
by Zacks Equity Research
Medtronic's (MDT) strategic acquisition of Companion Medical strengthens the company's data science and AI capabilities.
Looking for a Growth Stock? 3 Reasons Why Idexx (IDXX) is a Solid Choice
by Zacks Equity Research
Idexx (IDXX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
CVS Health Prescription Volume Solid, Price Cut Woes Stay
by Zacks Equity Research
CVS Health's (CVS) consumer centric digital strategy is even more relevant amid the pandemic.
IDEXX Laboratories' (IDXX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in IDEXX Laboratories (IDXX).
Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (IDXX) Outperforming Other Medical Stocks This Year?
Canopy Growth (CGC) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Continued momentum from robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in fiscal second quarter.
Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DEF
IDEXX (IDXX) Earnings Beat Estimates in Q3, Margins Rise
by Zacks Equity Research
IDEXX (IDXX) registered strong contribution from its CAG business in the third quarter despite pandemic-induced challenges.
Idexx Laboratories (IDXX) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 19.01% and 7.62%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Can Diagnostics Aid Hologic (HOLX) Q4 Sales Amid Coronavirus?
by Zacks Equity Research
Strength in Molecular Diagnostics business is likely to have continued to aid Hologic's (HOLX) performance in the fourth quarter of fiscal 2020 amid the coronavirus-led economic doldrums.
Owens & Minor (OMI) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Owens & Minor's (OMI) PPE sales are likely to have maintained its momentum during Q3, thus driving the top line.
STERIS (STE) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Within Life Sciences, STERIS (STE) might have registered benefit from pharma customers on growing vaccines and biologics businesses in Q2.
DexCom (DXCM) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
DexCom's (DXCM) third-quarter results benefit from solid segmental performance.
Quidel (QDEL) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Quidel's (QDEL) fiscal third-quarter results are likely to reflect solid show by Subscriptions and Managed Services segments.
Medical Products' Oct 29 Earnings Roster: SYK, BAX & More
by Trina Mukherjee
Medical Product companies have shown strength in the third quarter on the back of huge adoption of COVID-19 related healthcare-support products and services despite the impact of the ongoing pandemic.
Masimo (MASI) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
Masimo (MASI) continues to gain from key Product segment, which witnessed solid growth in Q3.
Varian (VAR) Earnings and Revenues Surpass Estimates in Q4
by Zacks Equity Research
Varian's (VAR) receipt of 10 Ethos orders in Q4 instills optimism
Why IDEXX Laboratories (IDXX) Might Surprise This Earnings Season
by Zacks Equity Research
IDEXX Laboratories (IDXX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Henry Schein (HSIC) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Henry Schein's (HSIC) medical business' PPE sales are likely to have maintained its momentum along with global recovery trends of the dental business during Q3.
LabCorp (LH) Q3 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
LabCorp (LH) Diagnostics business in Q3 grows significantly on organic volume improvements as a result of growing demand for COVID-19 testing.
ABIOMED (ABMD) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
The full commercial launch of Impella 5.5 in May is expected to have contributed to ABIOMED's (ABMD) fiscal second-quarter results
Quidel (QDEL) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Quidel (QDEL) is likely to have witnessed an uptick in rapid immunoassay revenues in Q3.
Ecolab (ECL) Earnings and Revenues Surpass Estimates in Q3
by Zacks Equity Research
Although Ecolab's (ECL) third-quarter results reflect weakness in the Global Industrial and Institutional segments, its Global Healthcare and Life Sciences unit shows strength.